ESTRO 2024 - Abstract Book

S2113

Clinical - Sarcoma, skin cancer, melanoma

ESTRO 2024

16 months. Grade 1/2 acute toxicities were noted in 66.7%, mainly fatigue, nausea and diarrhea. No grade 3 or higher acute and late toxicities were noted.

Figure 2. Patient with recurrent retroperitoneal leiomyosarcoma treated with PABR. Drastic symptomatic improvement was seen, and post-radiotherapy CT demonstrated a significant reduction in the tumour size within four months

Conclusion:

PABR for bulky, unresectable sarcomas appears to be safe and provides meaningful symptomatic response, tumour debulking, and durable local control. A prospective study of this novel approach is underway.

Keywords: Unresectable, Partially Ablative

References:

1. Lewis JJ, Leung D, Woodruff JM, Brennan MF. Retroperitoneal soft-tissue sarcoma: analysis of 500 patients treated and followed at a single institution. Ann Surg. 1998 Sep;228(3):355 – 65.

2. Judson I, Verweij J, Gelderblom H, Hartmann JT, Schöffski P, Blay JY, et al. Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial. Lancet Oncol. 2014 Apr;15(4):415 – 23.